Micro‐elimination of hepatitis C among people living with HIV in Egypt

Mohamed, Rahma; Cordie, Ahmed; Lazarus, Jeffrey V.; Esmat, Gamal

doi:10.1111/liv.14974

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, HCV elimination efforts met with participation and testing rate of 99.5% in a prison [83], 80% in a cohort of HIV-infected MSM [90], and 89% in an Egyptian village [88], where public health authorities engaged in short talks to address commonly asked questions, and distributed booklets, yers and posters before testing. With positive experience from HCV micro-elimination, public health agencies look forward to nationwide strategies for HCV elimination [95]- [99]. The overall strategic objective also includes elimination of HIV and STIs, because of the inherent similarities between the HCV and HIV and STI epidemiologies [1].…”

Section: Discussionmentioning

confidence: 99%

Impact of Voluntary Testing on Infectious Disease Epidemiology: A Game Theoretic Approach

Pepiot

Breban

2022

Preprint

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of Voluntary Testing on Infectious Disease Epidemiology: A Game Theoretic Approach

Pepiot

Breban

2022

Preprint

View full text Add to dashboard Cite

“…For example, HCV elimination efforts met with participation and testing rate of 99.5% in a prison [88], 80% in a cohort of HIV-infected MSM [95], and 89% in an Egyptian village [93], where public health authorities engaged in short talks to address commonly asked questions, and distributed booklets, flyers and posters before testing. With positive experience from HCV micro-elimination, public health agencies look forward to nationwide strategies for HCV elimination [100][101][102][103][104]. The overall strategic objective also includes elimination of HIV and STIs, because of the inherent similarities between the HCV and HIV and STI epidemiologies [1].…”

Section: Plos Onementioning

confidence: 99%

Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach

Pepiot,

Supervie,

Breban

2023

PLoS ONE

View full text Add to dashboard Cite

The World Health Organization recommends test-and-treat interventions to curb and even eliminate epidemics of HIV, viral hepatitis, and sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis and trichomoniasis). Epidemic models show these goals are achievable, provided the participation of individuals in test-and-treat interventions is sufficiently high. We combine epidemic models and game theoretic models to describe individual’s decisions to get tested for infectious diseases within certain epidemiological contexts, and, implicitly, their voluntary participation to test-and-treat interventions. We develop three hybrid models, to discuss interventions against HIV, HCV, and sexually transmitted infections, and the potential behavioral response from the target population. Our findings are similar across diseases. Particularly, individuals use three distinct behavioral patterns relative to testing, based on their perceived costs for testing, besides the payoff for discovering their disease status. Firstly, if the cost of testing is too high, then individuals refrain from voluntary testing and get tested only if they are symptomatic. Secondly, if the cost is moderate, some individuals will test voluntarily, starting treatment if needed. Hence, the spread of the disease declines and the disease epidemiology is mitigated. Thirdly, the most beneficial testing behavior takes place as individuals perceive a per-test payoff that surpasses a certain threshold, every time they get tested. Consequently, individuals achieve high voluntary testing rates, which may result in the elimination of the epidemic, albeit on temporary basis. Trials and studies have attained different levels of participation and testing rates. To increase testing rates, they should provide each eligible individual with a payoff, above a given threshold, each time the individual tests voluntarily.

show abstract

“…7 Additionally, lack of harm reduction measures for PWID, such as needle exchange programs, might further hinder HCV elimination. 8 According to a recent analysis, the WHO's 90% screening target was achieved in PWH and HCV in Europe, but the 80% treatment target was missed in all regions. 9 In Switzerland, low treatment uptake and high liver-related mortality was observed in people with HIV and HCV before the introduction of DAAs.…”

Section: Introductionmentioning

confidence: 99%

“…However, the availability of these drugs is limited due to their high cost and missing insurance‐coverage 7 . Additionally, lack of harm reduction measures for PWID, such as needle exchange programs, might further hinder HCV elimination 8 . According to a recent analysis, the WHO's 90% screening target was achieved in PWH and HCV in Europe, but the 80% treatment target was missed in all regions 9 …”

Section: Introductionmentioning

confidence: 99%

Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Baumann,

Braun,

Cavassini

et al. 2023

Liver International

View full text Add to dashboard Cite

Background and AimsTreatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver‐related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.MethodsWe included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver‐related mortality, as well as the yearly incidence of liver‐related events in persons with at least one documented positive HCV‐RNA.ResultsOf 14 652 participants under follow‐up, 2294 had at least one positive HCV‐RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient‐years (PY) to 1.1 per 100 PY, and incidence of liver‐related events decreased from 1.4/100 PY to 0.2/100 PY.ConclusionsThe introduction of DAA therapy was associated with a more than 10‐fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver‐related events declined substantially in persons living with HIV and hepatitis C.

show abstract

Micro‐elimination of hepatitis C among people living with HIV in Egypt

Cited by 4 publications

References 10 publications

Impact of Voluntary Testing on Infectious Disease Epidemiology: A Game Theoretic Approach

Impact of Voluntary Testing on Infectious Disease Epidemiology: A Game Theoretic Approach

Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach

Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Contact Info

Product

Resources

About